Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Vista Pharmaceuticals Limited

Market Cap 376M 3.99M 3.48M 3.22M 3.01M 5.65M 5.68M 38.18M 14.8M 185M 14.96M 14.64M 643M P/E 2024
-10.3x
P/E 2025 -13.6x
Enterprise Value 443M 4.69M 4.09M 3.79M 3.55M 6.65M 6.69M 44.95M 17.42M 218M 17.62M 17.24M 757M EV / Sales 2024
7.63x
EV / Sales 2025 8.85x
Free-Float
22.51%
Yield 2024 *
-
Yield 2025 -
02-13 Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
02-03 Vista Pharmaceuticals enters joint venture with Pleiades Therapeutics RE
25-08-13 Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
25-07-15 Vista Pharmaceuticals Limited announced that it has received INR 30.749994 million in funding CI
25-05-30 Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025 CI
25-02-18 Vista Pharmaceuticals Limited announced that it expects to receive INR 146.614482 million in funding CI
25-02-12 Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
24-11-13 Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024 CI
24-08-13 Vista Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2024 CI
24-05-28 Vista Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
24-02-10 Vista Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
24-01-07 Vista Pharmaceuticals Limited announced that it expects to receive INR 0.533334 million in funding CI
23-11-10 Vista Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
1 day-1.46%
1 week+0.14%
Current month-13.74%
1 month-0.67%
3 months-1.20%
6 months-10.62%
Current year-8.97%
1 week 6.95
Extreme 6.95
7.8
1 month 6.75
Extreme 6.75
8.6
Current year 5.71
Extreme 5.71
8.87
1 year 5.71
Extreme 5.71
11.69
3 years 5.71
Extreme 5.71
19.7
5 years 5.71
Extreme 5.71
19.7
10 years 4.51
Extreme 4.51
56.15
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - -
Compliance Officer - 2024-02-09
Director TitleAgeSince
Chairman 76 2014-01-01
Director/Board Member 76 2010-02-01
Director/Board Member 87 1993-06-15
Change 5-day change 1-year change 3-year change Capi.($)
-1.46%+0.14%-30.36%-30.16% 4.83M
+0.74%+1.69%+10.40%+85.32% 46.74B
-2.91%+3.09%+50.06%+90.35% 34.33B
-0.27%-2.71%-9.86%+33.69% 11.57B
-0.34%-3.07%+11.88%+92.57% 11.42B
-0.57%+0.96%+37.43%+128.26% 9.09B
+0.43%-1.68%+13.22%+41.07% 6.98B
+2.77%+1.83%+35.25%+243.81% 6.62B
-1.23%+1.65%+44.63%-18.54% 6.55B
+0.73%-2.94%-35.25%-2.32% 5B
Average -0.21%+0.51%+12.74%+66.41% 13.83B
Weighted average by Cap. -0.44%+0.99%+21.75%+82.93%

Financials

2024 2025
Net sales 103M 1.09M 951K 880K 824K 1.55M 1.56M 10.44M 4.05M 50.64M 4.09M 4M 176M 101M 1.07M 931K 862K 807K 1.51M 1.52M 10.23M 3.96M 49.59M 4.01M 3.92M 172M
Net income -45.12M -478K -417K -386K -361K -678K -682K -4.58M -1.78M -22.21M -1.79M -1.76M -77.11M -46.49M -493K -430K -398K -372K -698K -703K -4.72M -1.83M -22.88M -1.85M -1.81M -79.45M
Net Debt 78.7M 834K 727K 674K 631K 1.18M 1.19M 7.99M 3.1M 38.74M 3.13M 3.06M 135M 66.71M 707K 616K 571K 534K 1M 1.01M 6.77M 2.62M 32.84M 2.65M 2.6M 114M
Logo Vista Pharmaceuticals Limited
Vista Pharmaceuticals Limited is an India-based company, which is engaged in the manufacturing of pharmaceutical products. The Company offers over the counter and prescription generic drug products consisting of tablets, capsules and liquids covering various therapeutic categories. The Company has its United States Food and Drug Administration (USFDA) approved manufacturing facility in India and its marketing and distribution center in United States. Its products include tablet dosage forms and capsule dosage forms. The Company's tablet dosage forms in United States market include sulfamethoxazole & trimethoprim (400/80 mg) and acetaminophen (500 mg) film coated. The Company's tablet dosage forms in Non-United States market include aspirin (300, 325 & 500 mg), atenolol (50 & 100 mg), cotrimoxazole (480 mg), captopril (25 & 50 mg) and frusemide (40 mg). Its capsule dosage forms in Non-United States market include indomethacin (25 mg), piroxicam (10 & 20 mg) and nifedipine (10 mg).
Employees
30
Date Price Change Volume
26-06-18 7.410 -1.46% 840
26-06-17 7.520 +1.62% 13,903
26-06-16 7.400 +2.49% 2,811
26-06-15 7.220 -2.43% 13,367
26-06-12 7.400 +4.23% 2,652
  1. Stock Market
  2. Stocks
  3. VISTAPH6 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!